Autophagy, the mechanism by which cells deliver material to the lysosome, has been associated with resistance to anti-cancer drugs, leading autophagy inhibition to be widely studied as a potential chemosensitization strategy for cancer cells. This strategy is based on the idea that inhibition of autophagy will increase drug sensitivity and kill more cancer cells. Here we report an unintended negative effect of this strategy. When modeling the effect of drug resistance in a heterogeneous cancer cell population, we found that autophagy inhibition in drug sensitive tumor cells causes increased growth of drug resistant cells in the population through a mechanism involving caspase activation and prostaglandin E 2 signaling. These results emphasize the importance of understanding how autophagy manipulation in a tumor cell can have both cell-autonomous and nonautonomous effects, and suggest that attempts to chemosensitize by inhibiting autophagy could be enhanced by adopting methods aimed at reducing tumor repopulation.
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Abstract.
Autophagy, the mechanism by which cells deliver material to the lysosome, has been associated with resistance to anti-cancer drugs, leading autophagy inhibition to be widely studied as a potential chemosensitization strategy for cancer cells. This strategy is based on the idea that inhibition of autophagy will increase drug sensitivity and kill more cancer cells. Here we report an unintended negative effect of this strategy. When modeling the effect of drug resistance in a heterogeneous cancer cell population, we found that autophagy inhibition in drug sensitive tumor cells causes increased growth of drug resistant cells in the population through a mechanism involving caspase activation and prostaglandin E 2 signaling. These results emphasize the importance of understanding how autophagy manipulation in a tumor cell can have both cell-autonomous and nonautonomous effects, and suggest that attempts to chemosensitize by inhibiting autophagy could be enhanced by adopting methods aimed at reducing tumor repopulation.
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Introduction.
Macroautophagy (hereafter referred to as autophagy) is a mechanism whereby cellular material is engulfed in double membrane vesicles that fuse with lysosomes, resulting in the degradation of the engulfed material and recycling of macromolecular precursors. Autophagy has been widely studied in cancer where it is thought to have context-dependent roles that sometimes promote and sometimes suppress cancer (Galluzzi et al., 2015; White, 2012) . Autophagy manipulation (induced or inhibited autophagy) is of potential value in many diseases (Rubinsztein et al., 2012) . However, most current clinical studies that aim to target autophagy are in cancer and focus on autophagy inhibition (Kroemer, 2015; Thorburn et al., 2014a) . These studies all use lysosomal inhibitors of autophagy, chloroquine or hydroxychloroquine, in combination with another anti-cancer drug Mahalingam et al., 2014; Rangwala et al., 2014a; Rangwala et al., 2014b; Rosenfeld et al., 2014; Vogl et al., 2014) . The rationale for this approach is that autophagy inhibition will increase drug sensitivity in the tumor cells. This idea is based on in vitro and preclinical data showing chemosensitization effects by autophagy inhibition for many different classes of cancer drugs (Thorburn et al., 2014a) . Caution is warranted with this interpretation when only pharmacological approaches are used to inhibit autophagy, because chloroquine can chemosensitize and have anti-cancer effects by autophagy-independent mechanisms as well (Eng et al., 2016; Maycotte et al., 2012) . Nevertheless, a wealth of evidence using genetic, as well as pharmacological inhibition, of autophagy supports the idea that autophagy inhibition can increase cancer cell sensitivity to toxic insults and specifically anti-cancer drugs.
This article has not been copyedited and formatted. The final version may differ from this version. Intrinsic or acquired drug resistance is a major problem in cancer therapy (Holohan et al., 2013) , but the mechanisms that control growth of drug-resistant tumor cells are poorly understood. It is known that tumor cells that are killed by an anti-cancer treatment can affect tumor repopulation by drug-resistant cells that were not killed by the treatment. For example, apoptotic cells can promote growth of neighboring cells to promote tissue regeneration (Li et al., 2010) . This pathway, which involves caspase-3 activation, leads to increased prostaglandin E 2 (PGE 2 ) signaling and can promote tumor repopulation by cancer cells that were not killed by anti-cancer treatments (Huang et al., 2011) . Similarly, secretome-dependent signals from drug-treated tumor cells can promote drug resistance and tumor progression/metastasis (Obenauf et al., 2015) and PGE 2 -dependent signaling from dying tumor cells can stimulate cancer stem cell-mediated tumor repopulation (Kurtova et al., 2015) . Senescence-associated secretion also leads to non cell autonomous effects on neighboring cells and is linked with autophagy (Gewirtz, 2014) and recent studies show that non cell autonomous effects of autophagy in tumor stroma promotes growth of pancreas tumors through autophagic secretion of alanine (Sousa et al., 2016) . This raises an important question-does autophagy inhibition that is aimed at increasing sensitivity to anti-cancer drugs have effects on drug resistant cells in the population through non cell-autonomous mechanisms? To address this question, we modeled the effects of autophagy inhibition in drug-sensitive tumor cells in a mixed population of drug-resistant and drug-sensitive tumor cells and followed the effects on growth of the resistant cells. We found that selective inhibition of autophagy in drug sensitive cells can increase the growth of drug-resistant cells through caspase and PGE 2 signaling.
This article has not been copyedited and formatted. The final version may differ from this version. Matched drug-sensitive and -resistant Cell Lines. Construction of the GL261inducible shATG12 cell line was previously described (Macintosh et al., 2012) . GL261 cells do not express the Epidermal Growth Factor receptor (EGFR) and are therefore insensitive to diphtheria toxin-EGF (DT-EGF)-induced cell killing (Liu et al., 2003; Thorburn et al., 2009 (Thorburn et al., 2014b) . The GL261inducible shATG12 cells were transduced with retrovirus using 8 µg/ml polybrene and maintained with 0.5 µg/ml puromycin. To label DT-EGF resistant cells, the parental GL261 cell line (DT-EGF-resistant) was transduced with pLJM1-GFP-3xNLS-blasticidin lentivirus using 8 µg/ml polybrene and selected with 20 µg/ml blasticidin. After selection the cells were flow-sorted for the brightest cells (top 15%). MDA-MB-231-wt (sensitive to hTRAIL) and MDA-MB-231TRAIL-R (resistant to hTRAIL) matched cell lines were developed through long term exposure to increasing concentrations of hTRAIL (Dimberg et.al., submitted) . The MDA-MB-231TRAIL-R cells were transduced with pLJM1-GFP3xNLS-puromycin lentivirus using 8 µg/ml polybrene and selected with 1 µg/ml puromycin. After selection the cells were flow-sorted for the brightest cells (top 15%).
The parental BJAB cell line (sensitive to hTRAIL) and the BJAB LexR cell line (resistant to hTRAIL) were previously described (Menke et al., 2011) . For quantitation of the resistant cells, BJAB LexR cells were transduced with pMSCV luciferase PGKhygromycin retrovirus produced as described above using 8 µg/ml polybrene and selected with 400 µg/ml hygromycin. After selection the cells were used as a polyclonal population. (BJAB LexR -luc cell line). BJAB wt cells (TRAIL-sensitive) were plated at ~50,000 cells per 6 cm dish in 1.5 ml of medium containing polybrene at a final concentration of 8 µg/ml. The cells were This article has not been copyedited and formatted. The final version may differ from this version. 
Chemicals and
Clonogenic Growth Assays.
After doxycycline-induced shATG12 knockdown, described above, the GL261inducible shATG12-hEGFR cells (drug-sensitve cells) were also replated into 12 well plates (Corning #3512) at 20,000 cells per well either alone or together with 500 GL261-GFP cells (drug-resistant cells) in 1 ml of conditioned medium.
18-24 hours later the medium was changed for fresh conditioned medium (1 ml). Doses of DT-EGF were delivered in 1 µl of conditioned medium. Doxycycline was refreshed after 24 hours post drug treatment. 7 days post treatment the cells were fixed with 10%
MeOH, 10% glacial acetic acid in dH 2 O and stained with crystal violet. The crystal violet was resolubilized in 30% glacial acetic acid and analyzed at 540nM using a Benchmark Plus microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Experiments were performed in triplicate and repeated at least 3 times.
Results.
Growth of drug-resistance subsets of tumor cells following killing of drug sensitive tumor cells can explain how tumors become resistant to treatment. We were This article has not been copyedited and formatted. The final version may differ from this version. and stimulatory effects to autophagy inhibition (Guo et al., 2011; Maycotte et al., 2014) treatment with pharmacological autophagy inhibitors that would affect both drug sensitive and resistant cells equally is unable to rigorously test for non cell autonomous effects of autophagy in a heterogeneous tumor cell population. We previously reported that autophagy inhibition sensitizes cancer cells to TRAIL-induced apoptosis by making it easier for the cancer cells to activate caspases after mitochondrial membrane disruption (Thorburn et al., 2014b) . Therefore, to model non cell-autonomous effects of autophagy inhibition intended to chemosensitize tumor cells, we mixed isogenic Tumor Necrosis
Factor Related Apoptosis Inducing Ligand (TRAIL)-sensitive and TRAIL-resistant MDA-MB-231 breast tumor cells (Figure 1 ) so that the great majority (97.5%) of cells were sensitive to TRAIL-induced apoptosis with only a small minority of cells that were previously derived to be resistant to the drug and which were also stably expressing nuclear GFP. We blocked autophagy in the TRAIL-sensitive cells (but not the resistant cells) using shRNAs targeted to two essential autophagy regulators (ATG5 and ATG7), treated with doses of TRAIL sufficient to kill all the sensitive cells (Fig. 1A) , and monitored growth of the GFP-labeled resistant cells over several days (Fig. 1B) . This strategy allows detection of non cell-autonomous effects that specifically affect the resistant cells that were due to autophagy inhibition in the drug-sensitive cells. Figure 2 A-C shows that knockdown of ATG5 or ATG7 in the TRAIL-sensitive cells inhibited autophagic flux and caused an increase in the growth rate of the resistant cells.
This article has not been copyedited and formatted. The final version may differ from this version. Experiments using a different isogenic TRAIL-sensitive and TRAIL-resistant BJAB cell line pair (Menke et al., 2011) showed a similar growth promoting effect in resistant cells when autophagy was inhibited by ATG knockdown in sensitive cells ( Figure 2D ).
Caspase-mediated signaling through PGE 2 can promote tumor repopulation after radiotherapy or chemotherapy (Huang et al., 2011) . Because this mechanism is due to caspase activation, and we previously found that autophagy inhibition can increase caspase activation in response to apoptotic stimulus like TRAIL (Thorburn et al., 2014b) , we hypothesized that this mechanism is induced when autophagy is inhibited in drugsensitive tumor cells. A test of this hypothesis requires that caspases be inhibited and effects on the growth of drug-resistant cells then determined. This cannot be done using TRAIL as an anti-tumor agent because the drug-sensitive cells would not die with caspase inhibition, and thus the experiment would be unable to discriminate between an effect that was caused by caspase signaling itself or by the death of the cell. Therefore, to test if caspase activity is responsible for the autophagy inhibition mediated stimulation of drug-resistant cell growth, we need to kill drug sensitive tumor cells using an agent that can activate caspase-dependent apoptosis that is stimulated by autophagy inhibition but will still result in drug-induced tumor cell death even if caspases are blocked. To do this, we used a diphtheria toxin-EGF fusion protein (DT-EGF) that kills epidermal growth factor receptor (EGFR)-expressing cells (Liu et al., 2003) . We previously found that DT-EGF can kill glioma cells in both a caspase-dependent and caspase-independent manner.
When glioma cells are treated with DT-EGF, they die primarily by a caspase-independent mechanism. However, upon autophagy inhibition, caspase activation is increased and the preferred mode of death is by caspase-dependent apoptosis (Thorburn et al., 2009) . DTThis article has not been copyedited and formatted. The final version may differ from this version. Figure 3A) . And, as expected based on previous studies (Thorburn et al., 2009) , autophagy inhibition caused an increase in caspase activity in response to DT-EGF ( Figure 3B ). If a tumor repopulation mechanism like that previously described (Huang et al., 2011) These data indicate that it is not cell death itself that is responsible for the growth This article has not been copyedited and formatted. The final version may differ from this version. stimulation of the tumor cells that were not killed by the drug but rather the caspase activation and subsequent PGE 2 signaling. Thus, while autophagy inhibition can enhance the apoptosis response to an anti-cancer agent, this can lead to increased growth of any drug-resistant cancer cells in the population through a caspase-dependent and PGE 2 -dependent mechanism similar to that previously identified (Huang et al., 2011) .
Discussion.
A large number of studies have demonstrated that inhibition of autophagy can sensitize tumor cells to anti-cancer drugs (Levy and Thorburn, 2011; Rebecca and Amaravadi, 2015; Thorburn et al., 2014a) . This has led to dozens of clinical trials where autophagy inhibitors (so far, invariably chloroquine or hydroxychloroquine) are combined with other agents. An underlying rationale for these trials is that autophagy protects against tumor cell apoptosis. For example, autophagy inhibition causes an increase in the pro-apoptotic BH3 protein PUMA, which sensitizes tumor cells to TRAIL-induced apoptosis (Thorburn et al., 2014b) . Our studies identify an unexpected negative effect of this approach because autophagy inhibition in drug sensitive cells also causes more rapid growth of neighboring drug-resistant cells. This occurs through a mechanism of tumor repopulation, which is mediated by caspase activation and PGE 2 signaling from the dying apoptotic cells. Thus while autophagy inhibition may cause more effective tumor cell apoptosis, this might not always be a good thing in the long run if the end result is more rapid tumor repopulation from drug-resistant cells that were unable to be killed. Our results indicate that these effects are due to caspase activation (and PGE 2 signaling, which can be stimulated by caspases (Li et al., 2010) ) rather than This article has not been copyedited and formatted. The final version may differ from this version. cell death itself. Therefor, if one kills tumor cells by a mechanism other than caspasedependent apoptosis, it may be feasible to circumvent this growth stimulatory response.
Our experiments were done with mixed populations of isogenic tumor cells where only the resistant cells were marked with a fluorescent protein allowing them to be followed specifically. This allowed a rigorous assessment of non-cell autonomous effects of autophagy inhibition in the dying cells at drug doses that killed all the drug-sensitive cells, but also identifies a potential problem in studies intended to test if autophagy alters cancer cell chemosensitivity. Such studies usually involve inhibition of autophagy in a homogeneous population of drug-sensitive tumor cells followed by analysis of effects on tumor cell survival and growth. Because it is impossible to detect a sensitization or resistance effect of autophagy manipulation using drug doses that kill all the target cells, these experiments must be done at doses that are only partially effective. However, the mechanism identified here may lead to increased growth of cells that were not killed resulting in autophagy inhibition-mediated sensitization to the drug being underestimated or, especially with fast growing cells, even an apparent increase in overall number of drug treated cells when autophagy is blocked. Such an effect might cause an investigator to underestimate the chemosensitization effects of autophagy inhibition or mistakenly conclude that autophagy was necessary for tumor cell killing. This may explain some cases in the literature where autophagic cell death has been proposed to mediate chemotherapy effects (Thorburn et al., 2014a) .
In summary, the work described here identifies a potential problem with autophagy inhibition strategies designed to promote chemosensitization-improved druginduced tumor cell apoptosis achieved by autophagy inhibition may inadvertently also This article has not been copyedited and formatted. The final version may differ from this version. also overcome resistance to that drug (Ma et al., 2014) , and there are indications of clinical benefit in overcoming acquired resistance to vemurafenib when it is combined with chloroquine . 
